Combinational spinal GAD65 gene delivery and systemic GABA-mimetic treatment for modulation of spasticity.

PLoS One · 2012 · PMC3264568 · PMID 22291989

Europe PMC DOI

hedged sentences

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendp = 0.08so close (0.05 < p ≤ 0.1)

Similar analysis of GAD67 contact with VGluT1 terminals showed a trend towards reduction in animals with spasticity (1.8±0.1 in control vs. 1.2±0.06 in ischemic-spastic; p = 0.08).

also in 53,322 other papers

highly significantno p-value reported

In this combined therapy a potent and highly significant anti-spasticity effect was seen ( Fig. 3A, B ) the potency of which was similar to our previously reported anti-spasticity effect after intrathecal baclofen (GABA B receptor agonist; 1 μg) treatment using the same spinal ischemia-induced spasticity model [21] .

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.